This document discusses cerebral venous thrombosis (CVT), including:
1. CVT involves thrombosis of the dural sinuses and cerebral veins, most commonly affecting young individuals. Common risk factors relate to the Virchow triad of stasis, vessel wall changes, and hypercoagulability.
2. Clinical diagnosis is challenging, with headache being the most common symptom. Imaging plays a key role, with MRV and CTV being the primary modalities.
3. Treatment involves anticoagulation with heparin, with thrombolytic therapy considered for severe or worsening cases. Management also focuses on preventing complications like seizures, hydrocephalus, and intracranial hypertension.
RCVS is usually a benign cerebral vascular dysregulation induced clinico-radiological syndrome presents typically with recurrent thunderclap headache with or without ischemic/hemorrhagic stroke or cerebral edema with vasoconstriction. Various risk factors are responsible for this syndrome.
Intracerebral hemorhage Diagnosis and managementRamesh Babu
About ICH - Diagnosis and management, Discussed the clinical presentation, evaluation, radiological features and management including recent guidelines
Stroke in people under 45 years of age is less frequent than in older populations but has a major impact on the individual and society. In this article we provide an overview of the epidemiology and etiology of young stroke.
RCVS is usually a benign cerebral vascular dysregulation induced clinico-radiological syndrome presents typically with recurrent thunderclap headache with or without ischemic/hemorrhagic stroke or cerebral edema with vasoconstriction. Various risk factors are responsible for this syndrome.
Intracerebral hemorhage Diagnosis and managementRamesh Babu
About ICH - Diagnosis and management, Discussed the clinical presentation, evaluation, radiological features and management including recent guidelines
Stroke in people under 45 years of age is less frequent than in older populations but has a major impact on the individual and society. In this article we provide an overview of the epidemiology and etiology of young stroke.
Please find the power point on Management of Sub arachnoid hemorrhage. I tried to present it on understandable way and all the contents are reviewed by experts and from very reliable references. Thank you
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
5. Cerebral Venous Thrombosis:
• Thrombosis of the dural sinus and/or cerebral
veins (CVT).
• CVT represents 0.5% to 1% of all strokes.
– Roughly 5 people per million.
• More commonly seen in young individuals.
• 78% of 624 cases in International Study on
Cerebral Venous and Dural Sinuses(ISCVT)
Thrombosis occurred in patients < 50 years of
age.
7. Cause and Pathogenesis
• The risk factors for venous thrombosis in
general are linked classically to the Virchow
triad.
– stasis of the blood, changes in the vessel wall, and
changes in the composition of the blood.
• Acquired - surgery, trauma, pregnancy,
puerperium, antiphospholipid syndrome,
cancer, exogenous hormones
• Genetic causes- inherited thrombophilias.
8. Prothrombotic Conditions:
• Antithrombin III, Protein C, and Protein S
Deficiency.
• Antiphospholipid and Anticardiolipin
Antibodies.
• Factor V Leiden Gene Mutation and Resistance
to Activated Protein C.
• Prothrombin G20210A Mutation.
• Hyperhomocysteinemia.
9. Pregnancy and Puerperium:
• 2% of pregnancy-associated strokes are
attributable to CVT.
• Approximate frequency - 12 cases per 100 000
deliveries.
• During pregnancy (last trimester) and for 6 to
8 weeks after birth, women are at increased
risk of venous thromboembolic events.
• Increased prothrombotic factors, infection,
instrumentation, dehydration, cesarian, htn
10. Oral Contraceptives:
• 22 times more chance of having CVT than
those not using OCP’s.
• Presence of other thrombophilias increases
the risk further.
Cancer:
• Hematologic malignancies.
• Direct tumour compression.
• Hypercoagulable state associated with cancer
chemotherapeutic and hormonal agents
11. Para meningeal Infections:
• Infections of ear, sinus, mouth, face, and neck.
• 8.2% of all cases (ISCVT series).
• CVT caused by infection is more common in
children.
Other identified causes:
• paroxysmal nocturnal hemoglobinuria, iron
deficiency anemia, thrombocythemia, heparin-induced
thrombocytopenia, thrombotic
thrombocytopenic purpura, nephrotic syndrome,
inflammatory bowel disease, systemic lupus
erythematosus, Behçcet disease, mechanical
precipitants, epidural blood patch, spontaneous
intracranial hypotension, lumbar puncture.
12. Clinical Diagnosis of CVT:
• Clinical findings fall in to 2 categories.
– Those due to increased ICT
– Those due to focal brain infarction/ hemorrhage.
• Headache is the MC symptom – 90%.
– Diffuse and often progresses in severity over days
to weeks.
– minority of patients may present with thunderclap
headache.
– 25% with CVT can present with head and
papilledema alone.
13. • Venous infarction/ hemorrhage:
– Hemiparesis and aphasia MC
– Psychosis and other cortical dysfunction can occur.
• Superior sagittal sinus is most commonly
involved.
– Headache, increased intracranial pressure, and
papilledema.
– Motor deficit, seizure.
– Scalp edema and dilated scalp veins.
– Cortical involvement of frontal, parietal, occipital
areas.
14. • Lateral sinus thromboses:
– Features of middle ear infections.
– Increased intracranial pressure and distension of
the scalp veins.
– Hemianopia, contralateral weakness, and aphasia.
– Temporal cortical involvement seen.
• 16% of patients with CVT have thrombosis of
the deep cerebral venous system.
– thalamic or basal ganglia infarction.
– Decreased mentation, encephalopathy.
15. Features specific to CVT:
• Roughly 40% presents with partial/generalized
seizure.
• Relative bilateralism of symptoms/ signs/
imaging.
• Slowly progressive symptoms.
– In ISCVT: acute (<48 hours) in 37% of
patients,subacute (>48 hours to 30 days) in 56% of
patients, and chronic (>30 days) in 7% of patients.
16. Work Up:
• A complete blood count.
• Chemistry panel.
• Sedimentation rate.
• Measures of the prothrombin time and
activated partial thromboplastin time.
• Screening for potential prothrombotic
conditions that may predispose a person to
CVT.
17. • Lumbar Puncture:
– Elevated opening pressure in > 80%
– Unless there is clinical suspicion of meningitis,
examination of the cerebrospinal fluid (CSF) is
typically not helpful.
– Elevated cell counts (50%) and protein (35%) can
be seen.
18. D-Dimer:
• A product of fibrin degradation.
• Diagnostic role in exclusion of DVT.
• Sensitivity of 97.1%, a specificity of 91.2%, a negative
predictive value of 99.6%.
• A normal D-dimer level according to a sensitive
immunoassay or rapid enzyme-linked immunosorbent
assay (ELISA) may be considered to help identify
patients with low probability of CVT (Class IIb; Level
of Evidence B). If there is a strong clinical suspicion of
CVT, a normal D-dimer level should not preclude
further evaluation.
19. Common Pitfalls in the Diagnosis of
CVT:
• Intracranial Hemorrhage:
– 30% to 40% of patients with CVT present with ICH.
– Prodromal headache, bilateral parenchymal
abnormalities, and clinical evidence of a
hypercoagulable state.
– In patients with lobar ICH of otherwise unclear
origin or with cerebral infarction that crosses
typical arterial boundaries, imaging of the
cerebral venous system should be performed
(Class I; Level of Evidence C).
20. • Isolated Headache/Idiopathic Intracranial
Hypertension:
– Headache alone or headache and papilledema and/or
6th nerve palsy (25%).
– A new, atypical headache; headache that progresses
steadily over days to weeks despite conservative
treatment; and thunderclap headache can help
identify CVT.
– In patients with the clinical features of idiopathic
intracranial hypertension, imaging of the cerebral
venous system is recommended to exclude CVT (Class
I; Level of Evidence C).
– In patients with headache associated with atypical
features, imaging of the cerebral venous system is
reasonable to exclude CVT (Class IIa; Level of
Evidence C).
21. Imaging in the Diagnosis of CVT:
• Non Invasive Imaging:
– CT, MRI, Ultrasonography.
• Invasive Imaging:
– Cerebral Angiography and Direct Cerebral
Venography.
22. CT:
• Plain CT being abnormal only in <30% of CVT
cases.
• Hyperdensity of a cortical vein or dural sinus
seen.
• Acutely thromboses : Hyperdensity.
• Thrombosis of the posterior portion of the
superior sagittal sinus may appear as a dense
triangle – Dense delta sign.
• Ischemic infarction/hemorrhage may be seen.
– Not obeying any vascular territory.
23.
24. • Contrast-enhanced CT:
– filling defect within the vein or sinus.
– may show the classic “empty delta” sign, in which
a central hypointensity due to very slow or absent
flow within the sinus is surrounded by contrast
enhancement in the surrounding triangular shape
in the posterior aspect of the superior sagittal
sinus.
• CT Venogram.
25. Magnetic Resonance Imaging:
• MRI signal intensity vary according to duration of
the thrombus.
– 1st week : isointense to brain tissue on T1-weighted
images and hypointense on T2- weighted images.
– 2nd week - hyperintensity on T1- and T2-weighted
images.
• A thrombosed dural sinus or vein may then
demonstrate low signal on gradient-echo and
susceptibility-weighted images of magnetic
resonance images.
26. • Routine TOF MRV : absence of a flow void
with alteration of signal intensity in the dural
sinus indicate CVT.
• Contrast MRI – if TOF sequence inconclusive.
• Secondary changes: cerebral swelling, edema,
and/or hemorrhage.
• Focal edema without hemorrhage is visualized
on CT in about 8% of cases and on MRI in 25%.
• Focal parenchymal changes with edema and
hemorrhage may be identified in up to 40% of
patients.
27.
28. • Types of parenchymal hemorrhage in CVT:
– Brain parenchymal changes in frontal, parietal,
and occipital lobes usually correspond to superior
sagittal sinus thrombosis.
– Temporal lobe parenchymal changes correspond
to lateral (transverse) and sigmoid sinus
thrombosis.
– Thalamic hemorrhage, edema, or intraventricular
hemorrhage, correspond to thrombosis of the
vein of Galen or straight sinus.
29.
30.
31.
32. CT Venogram:
• More useful in sub acute
or chronic situations.
• Bone artefact may
interfere.
• CTV is at least equivalent
to MRV.
• Risk of radiation
exposure and iodine
contrast allergy.
33. Invasive Diagnostic Angiographic
Procedures:
• Cerebral Angiography and Direct Cerebral
Venography:
– Reserved for situations in which the MRV or CTV
results are inconclusive.
– If an endovascular procedure is being considered.
• Delayed phase of angiography shows sinus.
– CVT seen as filling defects or delay in visualization
of sinus.
– Normally 7 to 8 second after arterial phase.
34. • Direct Cerebral Venography Direct cerebral
venography is performed by direct injection of
contrast material into a dural sinus.
• Usually performed during endovascular
therapeutic procedures.
• Direct cerebral venography can identify
venous hypertension.
• Normal venous sinus pressure is 10 mm H2O.
• USS – more useful in neonates.
35.
36. Potential Pitfalls in the Radiological
Diagnosis of
CVT:
• Anatomic variants of normal venous anatomy
may mimic sinus thrombosis.
– Sinus atresia/hypoplasia, asymmetrical sinus
drainage, and normal sinus filling defects related
to prominent arachnoid granulations or intrasinus
septa.
• Studies show high prevalence of asymmetrical
lateral (transverse) sinuses (49%) and partial
or complete absence of 1 lateral sinus (20%).
37. • Hypoplastic dural sinus may have a more
tapering appearance than an abrupt defect in
contrast-enhanced images of the sinus.
38.
39. Imaging Recommendations:
• 1. Although a plain CT or MRI is useful in the initial evaluation of patients with
suspected CVT, a negative plain CT or MRI does not rule out CVT. A venographic
study (either CTV or MRV) should be performed in suspected CVT if the plain CT or
MRI is negative or to define the extent of CVT if the plain CT or MRI suggests CVT
(Class I; Level of Evidence C).
• 2. An early follow-up CTV or MRV is recommended in CVT patients with persistent
or evolving symptoms despite medical treatment or with symptoms suggestive of
propagation of thrombus (Class I; Level of Evidence C).
• 3. In patients with previous CVT who present with recurrent symptoms suggestive
of CVT, repeat CTV or MRV is recommended (Class I; Level of Evidence C).
• 4. Gradient echo T2 susceptibility-weighted images combined with magnetic
resonance can be useful to improve the accuracy of CVT diagnosis (Class IIa; Level of
Evidence B).
• 5. Catheter cerebral angiography can be useful in patients with inconclusive CTV or
MRV in whom a clinical suspicion for CVT remains high (Class IIa; Level of Evidence
C).
• 6. A follow-up CTV or MRV at 3 to 6 months after diagnosis is reasonable to assess
for recanalization of the occluded cortical vein/sinuses in stable patients (Class IIa;
Level of Evidence C).
40. Management and Treatment:
• Organized care is one of the most effective
interventions to reduce mortality and
morbidity after acute stroke.
• Management of CVT in a stroke unit is
reasonable for the initial management of CVT
to optimize care and minimize complications.
41. Initial Anticoagulation:
• Acute anticoagulation: Heparin is indicated.
• Presence of pre treatment ICH is not a
contraindication.
• No definite recommendation regarding
dosage.
• LMW heparin is preferred over UFH.
• Anticoagulation appears safe and effective.
42. Other Treatments:
• Fibrinolytic Therapy:
– 9% to 13% have poor outcomes despite
anticoagulation.
– Anticoagulation alone may not dissolve a large
and extensive thrombus.
– Partial or complete recanalization rates for CVT
ranged from 47% to 100% with anticoagulation
alone.
43. • Thrombolytic therapy is used if clinical
deterioration continues despite
anticoagulation or if a patient has elevated
intracranial pressure that evolves despite
other management approaches.
• Direct Catheter Thrombolysis.
• Mechanical Thrombectomy/Thrombolysis
– Balloon-Assisted Thrombectomy and
Thrombolysis.
– Catheter Thrombectomy.
• Surgical thrombectomy is rarely done.
44. • Aspirin has no role in the management of CVT.
• Steroids are contraindicated.
– Associated with high mortality and morbidity.
• Antibiotics – indicated if there is associated
infections.
45. Management and Prevention of Early
Complications:
• Seizures:
– Seizures are present in 37% of adults, 48% of
children, and 71% of newborns who present with
CVT.
– Seizures increase anoxic damage.
– Anticonvulsant treatment after even a single
seizure is reasonable.
– Prophylactic use of antiepileptic drugs may be
harmful.
46. • Early seizures indicate brain parenchymal
involvement.
– Supra tentorial lesions.
• Hydrocephalus
– Arachnoid granulation function may be impaired
and result in communicating hydrocephalus
(6.6%).
– obstructive hydrocephalus is less common – due
to ventricular hemorrhage.
– Raised ICT should be managed urgently as venous
pressure is already high.
47. • Intracranial Hypertension:
– 40% of patients with CVT present with isolated
intracranial hypertension.
– progressive headache, papilledema, and third or sixth
nerve palsies.
– Primarily caused by venous outflow obstruction and
tissue congestion compounded by CSF malabsorption.
– Acute setting: decompressive craniotomy.
– Proper anticoagulation
– Reasonable to initiate treatment with acetazolamide.
– Repeated LP or in C/c cases LP shunt.
– Steroids contraindicated.
– Evaluation of vision.
48. Long-Term Management and
Recurrence of CVT:
• The overall risk of recurrence of any thrombotic
event (CVT or systemic) after a CVT is around
6.5%.
• The risk of other manifestations of VTE after CVT
ranges from 3.4% to 4.3%.
• Male sex and polycythemia/thrombocythemia
being the only independent predictors in ISCVT
study.
• Systemic VTE after CVT is more common than
recurrent CVT.
49. • Thrombophilias have been stratified as mild or
severe on the basis of the risk of recurrence.
– Deficiencies of antithrombin, protein C, and
protein S, with a 19% recurrence at 2 years, 40%
at 5 years, and 55% at 10 years.
– Homozygous prothrombin G20210A; homozygous
factor V Leiden; deficiencies of protein C, protein
S, or antithrombin; combined thrombophilia
defects; and antiphospholipid syndrome are
categorized as severe.
• Testing to be done 2 to 4 weeks after
completion of anticoagulation.
50. Recommendations:
• In patients with provoked CVT (associated with a transient risk factor),
vitamin K antagonists may be continued for 3 to 6 months, with a
target INR of 2.0 to 3.0 (Table 3) (Class IIb; Level of Evidence C).
• In patients with unprovoked CVT, vitamin K antagonists may be
continued for 6 to 12 months, with a target INR of 2.0 to 3.0 (Class IIb;
Level of Evidence C).
• For patients with recurrent CVT, VTE after CVT, or first CVT with severe
thrombophilia (ie, homozygous prothrombin G20210A; homozygous
factor V Leiden; deficiencies of protein C, protein S, or antithrombin;
combined thrombophilia defects; or antiphospholipid syndrome),
indefinite anticoagulation may be considered, with a target INR of 2.0
to 3.0 (Class IIb; Level of Evidence C).
• Consultation with a physician with expertise in thrombosis may be
considered to assist in the prothrombotic testing and care of patients
with CVT (Class IIb; Level of Evidence C).
51. Management of Late Complications:
• Headache:
– 50%
– In Lille study 29% fulfilled criteria for migraine,
and 27% had headache of the tension type.
– In patients with persistent or severe headaches,
appropriate investigations should be completed to
rule out recurrent CVT.
– Lumbar puncture may be needed to exclude
elevated intracranial pressure.
52. • Seizures:
– Remote seizures affect 5% to 32% of patients.
– Most occur in the 1st yr of follow up.
– Risk factors for remote seizures- hemorrhagic
lesion on admission in MRI/CT, early seizure,
paresis.
• Visual Loss:
– More common in Pt with papilledema.
– Severe visual loss due to CVT rarely occurs (2 to
4%).
– Visual acuity and formal visual field testing should
be done.
53. • Dural Arteriovenous Fistula:
– Dural fistulas can be a late complication of
persistent dural sinus occlusion with increased
venous pressure.
– The fistula can close and cure if the sinus
recanalizes.
– A preexisting fistula can be the underlying cause
of CVT.
– A cerebral angiogram may help identify the
presence of a dural arteriovenous fistula.
54. CVT in Special Populations:
• CVT During Pregnancy:
– Incidence 1 in 2500 deliveries to 1 in 10 000
deliveries.
– Greatest risk - third trimester and the first 4
postpartum weeks.
– Up to 73% of CVT in women occurs during the
puerperium.
– Cesarean delivery appears to be associated with a
higher risk of CVT.
55. • Vitamin K antagonists are associated with fetal
embryopathy and HDN in neonates.
• UHF also causes teratogenicity and HDN.
• LMW Heparin is the drug of choice.
• No contra indication for future pregnancies.
• LMW Heparin during future pregnancies and
post partum period can be beneficial.
56. Recommendations:
• For women with CVT during pregnancy, LMWH in full
anticoagulant doses should be continued throughout
pregnancy, and LMWH or vitamin K antagonist with a target
INR of 2.0 to 3.0 should be continued for at least 6 weeks
postpartum (for a total minimum duration of therapy of 6
months) (Class I;Level of Evidence C).
• It is reasonable to advise women with a history of CVT that
future pregnancy is not contraindicated. Further investigations
regarding the underlying cause and a formal consultation with
a hematologist and/or maternal fetal medicine specialist are
reasonable.(Class IIa; Level of Evidence B).
• It is reasonable to treat acute CVT during pregnancy with full-dose
LMWH rather than UFH (Class IIa; Level of Evidence C).
• For women with a history of CVT, prophylaxis with LMWH
during future pregnancies and the postpartum period is
probably recommended (Class IIa; Level of Evidence C).
57. CVT in the Pediatric Population:
• Incidence - 0.67 per 100 000 children per year.
• Neonates present with seizures or lethargy.
• Older infants and children
– Present with seizures, altered levels of
consciousness, increasing headache with
papilledema, isolated intracranial hypertension, or
focal neurological deficits.
58. • Risk factors:
– Mechanical forces are exerted on the infant’s head
during birth.
– Increased thrombotic tendency of infants.
– Older children: systemic lupus erythematosus,
nephrotic syndrome, leukemia or lymphoma with
LL-asparaginase treatment, and trauma.
• Supportive measures for children with CVT
should include appropriate hydration, control
of epileptic Sz, and treatment of elevated
intracranial pressure.
59. • Periodic assesment of vision should be done.
• In children with acute CVT diagnosed beyond the
first 28 days of life, it is reasonable to treat with
full-dose LMWH even in the presence of
intracranial hemorrhage (Class IIa; Level of
Evidence C).
• In children with acute CVT diagnosed beyond the
first 28 days of life, it is reasonable to continue
LMWH or oral vitamin K antagonists for 3 to 6
months (Class IIa; Level of Evidence C).
60. • In neonates with acute CVT, treatment with
LMWH or UFH may be considered (Class IIb;
Level of Evidence B).
• Continuous electroencephalography
monitoring may be considered for individuals
who are unconscious or mechanically
ventilated.
• In neonates with acute CVT, continuation of
LMWH for 6 weeks to 3 months may be
considered (Class IIb; Level of Evidence C).